Physician profile
Kendall Smith
NPI 1366936833
$16,461.42
in general payments reported to CMS, 2019-2025
28 companies · $4,507 in 2025
The $4,507 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.75 · 2022: $3,408 · 2023: $2,660 · 2024: $5,827 · 2025: $4,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $2,170 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,502.69 |
| Consulting Fee | $2,170.00 |
| Education | $321.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $3,592.51 | 2022-2025 | Winlevi, Absorica Ld, Blu-U |
| Janssen Biotech, INC. | $1,696.12 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $1,674.43 | 2023-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,482.73 | 2022-2025 | |
| Ucb, INC. | $1,270.04 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $978.13 | 2023-2024 | Vtama |
| Incyte Corporation | $956.96 | 2022-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $861.16 | 2022-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $518.16 | 2023-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $497.63 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $458.85 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $448.94 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $432.68 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $282.60 | 2022-2024 | Olumiant, Taltz, Ebglyss |
| Organon LLC | $243.27 | 2025 | Vtama, Nexplanon, Hadlima |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $181.91 | 2022-2024 | Tremfya |
| Amgen INC. | $179.88 | 2024-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $179.61 | 2022-2025 | Arazlo, Jublia |
| Pfizer INC. | $118.78 | 2022-2025 | |
| Kyowa Kirin, INC. | $109.24 | 2023-2025 | Poteligeo |
| Stryker Corporation | $59.75 | 2021 | |
| Biofrontera INC. | $51.23 | 2022 | |
| Sanofi-Aventis U.S. LLC | $48.99 | 2025 | |
| Springworks Therapeutics, INC. | $41.38 | 2025 | Gomekli |
| Verrica Pharmaceuticals INC. | $31.42 | 2024 | Ycanth |
| Almirall LLC | $24.89 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $21.83 | 2022 | |
| Sandoz INC. | $18.30 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.